What Is 1mg of Wegovy
Wegovy (semaglutide) is a prescription injectable medication for chronic weight management. The standard maintenance dose is 2.4mg once weekly, but 1mg is a lower dose sometimes used in specific treatment plans or when titrating up. The 1mg dose is not the FDA-approved maintenance strength for weight loss, yet it appears in off-label or early-phase use contexts. Novo Nordisk manufactures Wegovy, and the company provides detailed prescribing information on its official site Novo Nordisk.
The 1mg dose is more commonly associated with Ozempic (semaglutide 1mg), which is approved for type 2 diabetes. Patients sometimes confuse the two because both use the same active ingredient at different strengths. Regulatory agencies classify Wegovy and Ozempic separately, with distinct approved indications, dosing schedules, and safety profiles.
Cost and Insurance Coverage for Wegovy at 1mg
Wegovy list price in the United States is high, often exceeding $1,300 per month without insurance. A 1mg dose may lower per-dose cost if used with lower-weight pens, but most insurance plans do not cover Wegovy for weight loss unless specific medical criteria are met. Manufacturer savings cards and pharmacy discount programs can reduce out-of-pocket costs, though coverage varies by plan and pharmacy U.S. Securities and Exchange Commission.
Public and private insurers increasingly require documented obesity-related conditions, such as hypertension or type 2 diabetes, before approving coverage. Some patients use international pharmacy services or mail-order options to reduce costs, but these channels carry regulatory and safety risks. The actual price a patient pays depends on deductible status, formulary placement, and manufacturer support programs.
Effectiveness, Safety, and Dosing Facts for 1mg Wegovy
Clinical trials for Wegovy used the 2.4mg weekly dose and showed average weight loss of around 15% of body weight over 68 weeks when combined with lifestyle changes. Data for a 1mg dose of semaglutide in weight management are limited, and no large-scale trial has established 1mg as a maintenance dose for obesity. Lower doses may reduce gastrointestinal side effects such as nausea, diarrhea, and constipation, which are common with GLP-1 receptor agonists Forbes.
Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and decreased appetite. Serious risks include pancreatitis, gallbladder problems, acute kidney injury, and potential thyroid tumors in animal studies. The FDA requires a boxed warning for thyroid C-cell tumors, and patients with a personal or family history of medullary thyroid carcinoma should not use Wegovy U.S. Food and Drug Administration.